RiVax™ – Key References

Posters:

1. Westfall J, Yates J, Van Slyke G, Measey T, Mantis N, Donini O. Using Monoclonal Antibodies as Immune Correlates of Protection: Thermostable Ricin Toxin Vaccine Development. Poster Presented at Chemical and Biological Defense Science and Technology Conference. **November 28-30, 2017.**
   View PDF file online
2. Donini O, Haulenbeek A, Arumugham R, Schaber C. Orphan Disease, Biodefense and the Animal Rule: A Thermostabilized Ricin Toxin Vaccine. Poster Presentated at the National Organization for Rare Diseases (NORD) Rare Diseases and Orphan Products Breakthrough Summit. **October 17-18, 2016**.
   View PDF file online
3. Roy, C.J., Mantis, N., Brey, R., Vitetta, E., Donini, O. Thermostable Subunit Vaccine Results in Protective Immunity in Rhesus Macaques in an Inhalational Ricin Model. Poster presentation at the 2015 Chemical Biological Defense Science and Technology conference. **May 12-14, 2015.**
   View PDF file online
4. Leffel, E., Roy, C.J., Brey, R.N., Donini, O. Thermostable Subunit Vaccine Results in Protective Immunity in Rhesus Macaques in an Inhalational Ricin Model. Poster Presentation at 2015 ASM Biodefense and Emerging Diseases Research Meeting. **February 9-11, 2015.**
   View PDF file online

Recent Papers:

1. Roy, C.J., Brey, R.N., Mantis, N.J., Mapes K., Pop, I.V., Pop, L.M., Ruback, S., Zilleen, S.Z., Doyle-Meyers, L., Vinet-Oliphant, H.S., Didier, P.J., Vitetta,, E.S. *Thermostable ricin vaccine protests rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection.* PNAS, 2015. **112**(12): 3782-87. http://www.pnas.org/content/112/12/3782.full.pdf
2. Vance, D.J., Rong, Y., Brey, R.N., Mantis, N.J. *Combination of two candidate subunit vaccine antigens elicits protective immunity to ricin and anthrax toxin in mice.* Vaccine, 2015. **33**(3): 417-21.

Papers:

1. Vitetta, E.S., et al., *A pilot clinical trial of a recombinant ricin vaccine in normal humans.* Proc Natl Acad Sci U S A, 2006. **103**(7): p. 2268-73.
2. Vitetta, E.S., J.E. Smallshaw, and J. Schindler, *A Small Phase IB Clinical Trial of an Alhydrogel-Adsorbed Recombinant Ricin Vaccine (RiVax).* Clin Vaccine Immunol, 2012.
3. Smallshaw, J.E., et al., *A novel recombinant vaccine which protects mice against ricin intoxication.* Vaccine, 2002. **20**(27-28): p. 3422-7.
4. Smallshaw, J.E., et al., *Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice.* Nat Biotechnol, 2003. **21**(4): p. 387-91.
5. Smallshaw, J.E., et al., *Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin.* Vaccine, 2005. **23**(39): p. 4775-84.
6. Smallshaw, J.E., J.A. Richardson, and E.S. Vitetta, *RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol.* Vaccine, 2007. **25**(42): p. 7459-69.
7. Smallshaw, J.E. and E.S. Vitetta, *A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity.* Vaccine, 2010. **28**(12): p. 2428-35.
8. Smallshaw, J.E. and E.S. Vitetta, *Ricin Vaccine Development.* Curr Top Microbiol Immunol, 2012. **357**: p. 259-72.
9. Peek, L.J., R.N. Brey, and C.R. Middaugh, *A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine.* J Pharm Sci, 2007. **96**(1): p. 44-60.

10. Maddaloni, M., et al., *Immunological characteristics associated with the protective efficacy of antibodies to ricin.* J. Immunol., 2004. **172**(10): p. 6221-8.
11. Legler, P.M., et al., *Structure of RiVax: a recombinant ricin vaccine.* Acta Crystallogr D Biol Crystallogr, 2011. **67**(Pt 9): p. 826-30.
12. Baluna, R., et al., *Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.* Proc Natl Acad Sci U S A, 1999. **96**(7): p. 3957-62.

13. Brey, R.N. and N.J. Mantis, *Ricin: A type II ribosome inactivating protein*, in *Vaccines for Biodefense and Neglected Diseases*, A. Barrett, Editor. 2008, Elsevier. p. 1100-1115.
14. Audi, J., et al., *Ricin poisoning: a comprehensive review.* JAMA, 2005. **294**(18): p. 2342-51.
15. Barbieri, L., M.G. Battelli, and F. Stirpe, *Ribosome-inactivating proteins from plants.* Biochim Biophys Acta, 1993. **1154**(3-4): p. 237-82.
16. Bozzette, S.A., et al., *A model for a smallpox-vaccination policy.* N Engl J Med, 2003. **348**(5): p. 416-25.
17. Bradberry, S.M., et al., *Ricin poisoning.* Toxicol Rev, 2003. **22**(1): p. 65-70.
18. Brown, R.F. and D.E. White, *Ultrastructure of rat lung following inhalation of ricin aerosol.* Int J Exp Pathol, 1997. **78**(4): p. 267-76.
19. Castelletti, D., et al., *A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.* Clin Exp Immunol, 2004. **136**(2): p. 365-72.
20. Compton, J.R., et al., *Introduction of a disulfide bond leads to stabilization and crystallization of a ricin immunogen.* Proteins, 2011. **79**(4): p. 1048-60.
21. Dormitzer, P.R., J.B. Ulmer, and R. Rappuoli, *Structure-based antigen design: a strategy for next generation vaccines.* Trends Biotechnol, 2008. **26**(12): p. 659-67.
22. Eiklid, K., S. Olsnes, and A. Pihl, *Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells.* Exp Cell Res, 1980. **126**(2): p. 321-6.
23. El, S.-C., et al., *Progressive circumscribed sclerosis--a novel side-effect of immunotherapy with aluminium-adsorbed allergen extracts.* Allergy, 2009. **64**(6): p. 965-7.
24. Endo, Y. and K. Tsurugi, *RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes.* J Biol Chem, 1987. **262**(17): p. 8128-30.
25. Flacher, V., et al., *Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis.* J Invest Dermatol, 2010. **130**(3): p. 755-62.
26. Furukawa-Stoffer, T.L., et al., *A novel biological-based assay for the screening of neutralizing antibodies to ricin.* Hybridoma, 1999. **18**(6): p. 505-11.
27. Hewetson, J.F., Rivera, V.R., Lemley, P.V., Pitt, M.L., Creasia, D.A., Thompson, W.L., *A formalinized toxoid for protection of mice with inhaled ricin*. Vaccine Res, 1995. **4**: p. 179-87.
28. Hewetson, J.F., et al., *Protection of mice from inhaled ricin by vaccination with ricin or by passive treatment with heterologous antibody*. Vaccine, 1993. **11**(7): p. 743-6.
29. Hewetson JF, A.A., Teters DR, Kotes JM, Washington E, Tamariello R, *et al*., *Immune response and protection of rats and mice from ricin aerosol exposure after vaccination with deglycosylated ricin A chain (Abstract).* Fundam Appl Toxicol, 1996. **30(Suppl.)**: p. 59.
30. Holmes RK, J.M., Connell TD, *Bacterial toxins and virulence factors in disease*. Cholera toxin and related enterotoxins of gram-negative bacteria, ed. V.M. Moss BIJ, Tu AT. 1995, New York: Marcel Dekker, Inc.
31. Hunter, R.L., *Overview of vaccine adjuvants: present and future.* Vaccine, 2002. **20 Suppl 3**: p. S7-12.
32. Jefferson, T., M. Rudin, and C. Di Pietrantonj, *Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence.* Lancet Infect Dis, 2004. **4**(2): p. 84-90.
33. Kim, Y. and J.D. Robertus, *Analysis of several key active site residues of ricin A chain by mutagenesis and X-ray crystallography.* Protein Eng, 1992. **5**(8): p. 775-9.
34. Lemley, P.V., P. Amanatides, and D.C. Wright, *Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo.* Hybridoma, 1994. **13**(5): p. 417-21.
35. Lindstrom, A.L. and C.A. Pennell, *In vitro studies of ricin A-chain-induced vascular leak syndrome.* Methods Mol Biol, 2001. **166**: p. 125-35.
36. Lord, J.M., L.M. Roberts, and J.D. Robertus, *Ricin: structure, mode of action, and some current applications.* FASEB J, 1994. **8**(2): p. 201-8.

37. Marconescu, P.S., et al., *Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication.* Vaccine, 2010. **28**(32): p. 5315-22.
38. Mastri, M., et al., *Activation of Toll-like receptor 3 (TLR3) amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency.* Am J Physiol Cell Physiol, 2012.
39. Mathias-Santos, C., et al., *Distinctive immunomodulatory and inflammatory properties of the Escherichia coli type II heat-labile enterotoxin LT-IIa and its B pentamer following intradermal administration.* Clin Vaccine Immunol, 2011. **18**(8): p. 1243-51.
40. McHugh, C.A., et al., *Improved stability of a protein vaccine through elimination of a partially unfolded state.* Protein Sci, 2004. **13**(10): p. 2736-43.
41. McLain, D.E., et al., *Progress in Biological Threat Agent Vaccine Development: A Repeat-Dose Toxicity Study of a Recombinant Ricin Toxin A-Chain (rRTA) 1-33/44-198 Vaccine (RVEc) in Male and Female New Zealand White Rabbits.* Int J Toxicol, 2011.
42. McLain, D.E., et al., *Protective Effect of Two Recombinant Ricin Subunit Vaccines in the New Zealand White Rabbit Subjected to a Lethal Aerosolized Ricin Challenge: Survival, Immunological Response and Histopathological Findings.* Toxicol Sci, 2011.
43. Meagher, M.M., et al., *Process development and cGMP manufacturing of a recombinant ricin vaccine: An effective and stable recombinant ricin a-chain vaccine-RVEc.* Biotechnol Prog, 2011.
44. Neal, L.M., et al., *A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin.* Infect Immun, 2010. **78**(1): p. 552-61.
45. O'Hara, J.M., et al., *Folding domains within the ricin toxin A subunit as targets of protective antibodies.* Vaccine, 2010. **28**(43): p. 7035-46.
46. O'Hara, J.M., A. Yermakova, and N.J. Mantis, *Immunity to ricin: fundamental insights into toxin-antibody interactions.* Curr Top Microbiol Immunol, 2012. **357**: p. 209-41.
47. Olsnes, S., *The history of ricin, abrin and related toxins.* Toxicon, 2004. **44**(4): p. 361-70.
48. Olson, M.A., *Ricin A-chain structural determinant for binding substrate analogues: a molecular dynamics simulation analysis.* Proteins, 1997. **27**(1): p. 80-95.
49. Olson, M.A., et al., *Finding a new vaccine in the ricin protein fold.* Protein Eng Des Sel, 2004. **17**(4): p. 391-7.
50. Porter, A., et al., *Evaluation of a ricin vaccine candidate (RVEc) for human toxicity using an in vitro vascular leak assay.* Toxicon, 2011. **58**(1): p. 68-75.
51. Radosavljevic, V. and G. Belojevic, *A new model of bioterrorism risk assessment.* Biosecur Bioterror, 2009. **7**(4): p. 443-51.
52. Ramasamy, S., et al., *Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.* Br J Pharmacol, 2010. **161**(4): p. 721-48.
53. Ready, M.P., Y. Kim, and J.D. Robertus, *Site-directed mutagenesis of ricin A-chain and implications for the mechanism of action.* Proteins, 1991. **10**(3): p. 270-8.
54. Reinhardt, R.L., H.E. Liang, and R.M. Locksley, *Cytokine-secreting follicular T cells shape the antibody repertoire.* Nat Immunol, 2009. **10**(4): p. 385-93.
55. Reisler, R.B. and L.A. Smith, *The need for continued development of ricin countermeasures.* Adv Prev Med, 2012. **2012**: p. 149737.
56. Remot, A., et al., *Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine.* PLoS One, 2012. **7**(5): p. e37722.
57. Roche, J.K., et al., *Post-exposure targeting of specific epitopes on ricin toxin abrogates toxin-induced hypoglycemia, hepatic injury, and lethality in a mouse model.* Lab Invest, 2008. **88**(11): p. 1178-91.
58. Romani, N., et al., *Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy.* Immunol Cell Biol, 2010. **88**(4): p. 424-30.
59. Rutenber, E., M. Ready, and J.D. Robertus, *Structure and evolution of ricin B chain.* Nature, 1987. **326**(6113): p. 624-6.

60. Rutenber, E. and J.D. Robertus, *Structure of ricin B-chain at 2.5 A resolution.* Proteins, 1991. **10**(3): p. 260-9.
61. Soler-Rodriguez, A.M., et al., *Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome.* Exp Cell Res, 1993. **206**(2): p. 227-34.
62. Thomas, J.C., et al., *Effect of single-point mutations on the stability and immunogenicity of a recombinant ricin A chain subunit vaccine antigen.* Hum Vaccin Immunother, 2013. **9**(4).
63. Tommasi, M., et al., *Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones.* Clin Exp Immunol, 2001. **125**(3): p. 391-400.
64. Verma, A., et al., *Use of site-directed mutagenesis to model the effects of spontaneous deamidation on the immunogenicity of Bacillus anthracis protective antigen.* Infect Immun, 2013. **81**(1): p. 278-84.
65. Vogelbruch, M., et al., *Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations.* Allergy, 2000. **55**(9): p. 883-887.
66. Wang, Y., et al., *Novel chimeric anti-ricin antibody C4C13 with neutralizing activity against ricin toxicity.* Biotechnol Lett, 2007. **29**(12): p. 1811-6.
67. Yermakova, A. and N.J. Mantis, *Protective immunity to ricin toxin conferred by antibodies against the toxin's binding subunit (RTB).* Vaccine, 2011. **29**(45): p. 7925-35.